A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is sold under the brand name Mounjaro and affects feelings of hunger and fullness,

Both Wegovy and Mounjaro are given as weekly injections via pre-filled pens that can be self-administered into the upper arm, thigh or stomach. They work as an appetite suppressant by mimicking a hormone called glucagon-like peptide-1 (GLP-1).

The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will study the impact of a weight-loss drug on work and productivity.

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its shortage list. Here's what taking the drug of the list could mean for people taking tirzepatide or its compounded versions.

Diabetes and weight loss drugs like Mounjaro and Ozempic may also help patients suffering from addiction, according to a new study. In the study, published Thursday in the scientific journal Addiction,

Streeting announced a collaboration with the world's largest pharmaceutical company, Lilly, which will include a five-year trial investigating whether the use of the weight-loss drug tirzepatide helps get people back into employment.

Research hints that medications like Zepbound and Wegovy could provide new ways to treat opioid and alcohol abuse.

Many people use semaglutides like Ozempic for weight loss, but can you use it to lose a small amount—say, 10 or 20 pounds? Doctors explain the concerns.

A recent study revealed that weight loss medications like Ozempic and Mounjaro might help individuals battling addiction. The findings, published in the scientific journal Addiction, said that people with alcohol addiction who were prescribed these medications had a 50 per cent lower rate of binge drinking compared to those who were not.